Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.64 |
| ▸ | CES1 | P23141 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.61 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | CTNNB1 | P35222 | 5/20 | 0.58 |
| ▸ | WNT3A | P56704 | 3/20 | 0.56 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29355245 | 1.00 | CES2 (0.64) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL33721999 | 0.91 | CES2 (0.59) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL2544523 | 0.91 | CES2 (0.59) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL4625845 | 0.90 | KMT2A (0.63) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL9493294 | 0.90 | LMNA (0.61) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL5159751 | 0.88 | CES2 (0.55) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL1360847 | 0.88 | ALDH1A1 (0.62) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL29740682 | 0.88 | ALDH1A1 (0.62) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL2470002 | 0.86 | CTNNB1 (0.71) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL30534787 | 0.86 | ALDH1A1 (0.60) | CES2CES1L3MBTL1LMNANAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240093086-A1 | HYDROPHIBIC CARBON-DOTS FOR OIL TRACERS | ARAMCO SERVICES COMPANY (US) | 2024-03-21 | — | — | US | claimed |
| US-20230406990-A1 | REACTIVE COMPOUND FOR PRODUCING POLYURETHANE LAYERS HAVING THERMALLY ACTIVATABLE CATALYST SYSTEMS | BENECKE-KALIKO AG (DE) | 2023-12-21 | — | — | US | claimed |
| EP-4214255-A1 | REACTIVE COMPOUND FOR PRODUCING POLYURETHANE LAYERS HAVING THERMALLY ACTIVATABLE CATALYST SYSTEMS | Benecke-Kaliko AG (DE) | 2023-07-26 | — | — | EP | claimed |
| CN-116096772-A | Reactive mixtures for producing polyurethane layers with heat-activatable catalyst systems | 贝内克-凯利科股份公司 | 2023-05-09 | — | — | CN | claimed |
| WO-2022057985-A1 | REACTIVE COMPOUND FOR PRODUCING POLYURETHANE LAYERS HAVING THERMALLY ACTIVATABLE CATALYST SYSTEMS | BENECKE-KALIKO AG (DE) | 2022-03-24 | — | — | WO | claimed |
| US-12570771-B2 | Curing catalyst used for curing of polymer, production method for said curing catalyst, mositure-curable composition, and production method for cured product | NITTO KASEI CO., LTD. (JP) | 2026-03-10 | — | — | US | disclosed |
| EP-4682204-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2026-01-21 | — | — | EP | disclosed |
| US-12522591-B2 | Materials for organic electroluminescent devices | MERCK PATENT GMBH (DE) | 2026-01-13 | — | — | US | disclosed |
| US-12516157-B2 | Curing catalyst used for curing polymer, method for producing same, moisture-curable composition, and method for producing cured product | NITTO KASEI CO., LTD. (JP) | 2026-01-06 | — | — | US | disclosed |
| US-12514107-B2 | Organic electroluminescent apparatus | MERCK PATENT GMBH (DE) | 2025-12-30 | — | — | US | disclosed |
| EP-4180482-B1 | MOISTURE-CURABLE COMPOSITION | NITTO KASEI CO LTD (JP) | 2025-12-03 | — | — | EP | disclosed |
| EP-4656672-A1 | METHOD FOR PRODUCING CURABLE COMPOSITION | Kaneka Corporation (JP) | 2025-12-03 | — | — | EP | disclosed |
| WO-2011051540-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2011-05-05 | — | — | WO | disclosed |
| US-7880013-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100256361-A1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-7718808-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20070132366-A1 | Light emitting device and lighting device using it, image display unit | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-06-14 | — | — | US | disclosed |
| US-20070132366-A1 | Light emitting device and lighting device using it, image display unit | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-06-14 | — | — | US | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1700856-A1 | THIAZOLE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570771-B2 | Curing catalyst used for curing of polymer, production method for said curing catalyst, mositure-curable composition, and production method for cured product | RPS6KB1, RPS6KA1, RPS6KB2 | CES2 1603/4885CES1 697/4885L3MBTL1 2074/4885 |
| US-20100256361-A1 | THIAZOLE DERIVATIVES | ADORA2A, ADORA3, ADORA1 | CES2 798/4885CES1 1610/4885L3MBTL1 2618/4885 |
| US-12514107-B2 | Organic electroluminescent apparatus | SCO2, RIF1, RER1 | CES2 2137/4885CES1 3863/4885L3MBTL1 1903/4885 |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | ADORA2A, ADORA3, ADORA1 | CES2 1189/4885CES1 3277/4885L3MBTL1 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.